359 research outputs found
Wielka unifikacja ekologiczna. Ecologia humana jako odpowiedź na kryzys ekologiczny
"Sytuacja globalnego kryzysu ekologicznego zainspirowała powstanie szeregu koncepcji
podejmujących integralną analizę kwestii społecznych, technicznych, gospodarczych,
przyrodniczych i etycznych w celu zbudowania nowych modeli rozwoju
świata. Obserwując bowiem sposób życia we współczesnej cywilizacji nie sposób
nie pytać, jak powinny się zmienić ludzkie preferencje i instytucje, w których żyjemy,
aby zachować świat i dla przyszłych generacji? Jak wielkie i głębokie powinny
być zmiany, aby Ziemia dalej była gościnnym, cennym i różnorodnym domem
dla wszystkich jej mieszkańców?
Podstawową kwestią wyjściową staje się pytanie jak realizować nasze niekończące
się pragnienia w skończonym i ograniczonym świecie?"(...
Veteris et recentioris philosophiae dogmata Joannis Dunsii Scoti, subtilium principis doctoris accomodata : atque in tres tomos distributa
Datos de ed. preceden a "tomus primus"Sign.: A-Z4, 2A-2Z4, 3A-3K4.Texto a dos col
Elementa philosophiae in adolestentium usum
Contiene: T.I Philosophiae prolegomena, Elementa logicae, Elementa metaphysicae (VIII, 310 p., [2] h. pleg. de lám.) -- T.II Physicae generalis elementa (272 p., [3] h. pleg. de lám.) -- T.III Physicae particularis elementa (310 p., [3] h. pleg. de lám.) -- T.IV Physicae particularis elementa (324 p., [3] h. pleg. de lám.)Copia digital. España : Ministerio de Educación, Cultura y Deporte. Subdirección General de Coordinación Bibliotecaria, 201
Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients
Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed to assess whether CP administered during the first week of symptoms reduced the disease progression or risk of hospitalization of outpatients. Two multicenter, double-blind randomized trials (NCT04621123, NCT04589949) were merged with data pooling starting when = 50 years and symptomatic for <= 7days were included. The intervention consisted of 200-300mL of CP with a predefined minimum level of antibodies. Primary endpoints were a 5-point disease severity scale and a composite of hospitalization or death by 28 days. Amongst the 797 patients included, 390 received CP and 392 placebo; they had a median age of 58 years, 1 comorbidity, 5 days symptoms and 93% had negative IgG antibody-test. Seventy-four patients were hospitalized, 6 required mechanical ventilation and 3 died. The odds ratio (OR) of CP for improved disease severity scale was 0.936 (credible interval (CI) 0.667-1.311); OR for hospitalization or death was 0.919 (CI 0.592-1.416). CP effect on hospital admission or death was largest in patients with <= 5 days of symptoms (OR 0.658, 95%CI 0.394-1.085). CP did not decrease the time to full symptom resolution
High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial.
BACKGROUND: Convalescent plasma has been proposed as an early treatment to interrupt the progression of early COVID-19 to severe disease, but there is little definitive evidence. We aimed to assess whether early treatment with convalescent plasma reduces the risk of hospitalisation and reduces SARS-CoV-2 viral load among outpatients with COVID-19. METHODS: We did a multicentre, double-blind, randomised, placebo-controlled trial in four health-care centres in Catalonia, Spain. Adult outpatients aged 50 years or older with the onset of mild COVID-19 symptoms 7 days or less before randomisation were eligible for enrolment. Participants were randomly assigned (1:1) to receive one intravenous infusion of either 250-300 mL of ABO-compatible high anti-SARS-CoV-2 IgG titres (EUROIMMUN ratio ≥6) methylene blue-treated convalescent plasma (experimental group) or 250 mL of sterile 0·9% saline solution (control). Randomisation was done with the use of a central web-based system with concealment of the trial group assignment and no stratification. To preserve masking, we used opaque tubular bags that covered the investigational product and the infusion catheter. The coprimary endpoints were the incidence of hospitalisation within 28 days from baseline and the mean change in viral load (in log10 copies per mL) in nasopharyngeal swabs from baseline to day 7. The trial was stopped early following a data safety monitoring board recommendation because more than 85% of the target population had received a COVID-19 vaccine. Primary efficacy analyses were done in the intention-to-treat population, safety was assessed in all patients who received the investigational product. This study is registered with ClinicalTrials.gov, NCT04621123. FINDINGS: Between Nov 10, 2020, and July 28, 2021, we assessed 909 patients with confirmed COVID-19 for inclusion in the trial, 376 of whom were eligible and were randomly assigned to treatment (convalescent plasma n=188 [serum antibody-negative n=160]; placebo n=188 [serum antibody-negative n=166]). Median age was 56 years (IQR 52-62) and the mean symptom duration was 4·4 days (SD 1·4) before random assignment. In the intention-to-treat population, hospitalisation within 28 days from baseline occurred in 22 (12%) participants who received convalescent plasma versus 21 (11%) who received placebo (relative risk 1·05 [95% CI 0·78 to 1·41]). The mean change in viral load from baseline to day 7 was -2·41 log10 copies per mL (SD 1·32) with convalescent plasma and -2·32 log10 copies per mL (1·43) with placebo (crude difference -0·10 log10 copies per mL [95% CI -0·35 to 0·15]). One participant with mild COVID-19 developed a thromboembolic event 7 days after convalescent plasma infusion, which was reported as a serious adverse event possibly related to COVID-19 or to the experimental intervention. INTERPRETATION: Methylene blue-treated convalescent plasma did not prevent progression from mild to severe illness and did not reduce viral load in outpatients with COVID-19. Therefore, formal recommendations to support the use of convalescent plasma in outpatients with COVID-19 cannot be concluded. FUNDING: Grifols, Crowdfunding campaign YoMeCorono
Título: Disputationes theologicae : in tertium librum sententiarum ...
Sign.: a, A-Z, 2A-2B, 2CPort. con grav. xilTexto a dúas co
Elementa philosophiae : in adolescentium usum ex probatis auctoribus
Sign.: A-LAs f. de grav. son calc. e representan táboas de físic
Physica experimentalis et rationalis : ad gustum moderni saeculi, pro jucundidate utilitateque discentium, methodo clara et systematica
Sign.: 3M-3Z\p8\s, 4A-4Z\p8\s, 5A-5H\p8\s, 5I\p2\sTexto con apostillas marxinai
- …